Jasper Therapeutics and Aruvant Sciences are studying the use of JSP191 used with ARU-1801 in patients with sickle cell disease.
C. Ola Landgren, MD, PhD, discussed the role of CAR T-cell therapies in myltiple myeloma.
James Hoffman, MD, discussed the significance of the approval of ide-cel for patients with multiple myeloma.
Faith E. Davies, MD, discussed the potential of CAR T-cell therapies for the treatment of multiple myeloma.
At the 18-month follow-up, the CAR T-cell therapy led to early, deep, and durable responses with a manageable safety profile in patients with relapsed/refractory multiple myeloma.